Cancer Family
Musculoskeletal Neoplasm
CI-CAN-00000278Explore in graph →
Non-malignant212 active trials5 approved drugs54 evidence items
- NCIt
- C166354
Loading cancer entity…
Cancer Family
CI-CAN-00000278Explore in graph →
Clinical trials
1,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH |
| 3 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT04807816 | Targeting ATR in Soft-tissue Sarcomas(TARSARC) | completed | Phase 2 | 58 | Institut BergoniéOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT02945800 | Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma | completed | Phase 2 | 59 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06562673 | Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma(IACE-OS) | completed | Phase 1 / Phase 2 | 10 | Shanghai 6th People's HospitalOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT03526679 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma(LEADER) | completed | Phase 1 / Phase 2 | 30 | National Taiwan University HospitalOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT00492817 | Evaluation of Single Session Stereotactic Body Radiotherapy | completed | Phase 1 / Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05080790 | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma(DiTuSarc) | completed | Phase 2 | 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT04963517 | Exercise Intervention for Bone Tumor Patients(proGAIT) | completed | Phase 2 / Phase 3 | 11 | Universität Duisburg-EssenOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas(ImmunoSarc) | completed | Phase 1 / Phase 2 | 197 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Aug 13, 2024 | clinicaltrials |
| NCT00290251 | Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 | completed | Phase 2 | 72 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 15, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT04310410 | Feasibility of Combined Focused Ultrasound and Radiotherapy Treatment in Patients With Painful Bone Metastasis(PRE-FURTHER) | completed | Phase 1 / Phase 2 | 10 | UMC UtrechtOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT01336803 | Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI(Osteosarcoma) | completed | Phase 2 | 32 | Heike E Daldrup-LinkOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT02048371 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | completed | Phase 2 | 131 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02584309 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 73 | Washington University School of MedicineOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT02500797 | Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 164 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT00667342 | A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma | completed | Phase 2 | 43 | St. Jude Children's Research HospitalOTHER | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03718091 | M6620 (VX-970) in Selected Solid Tumors | completed | Phase 2 | 30 | Massachusetts General HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT04071574 | Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility(CS-EOSP-ICSI) | completed | Phase 1 / Phase 2 | 200 | Lebanese UniversityOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | completed | Phase 2 | 535 | AmgenINDUSTRY | 12 | Sep 22, 2022 | clinicaltrials |
| NCT03245450 | Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 40 | Eisai Inc.INDUSTRY | 8 | Jun 28, 2022 | clinicaltrials |
| NCT02821507 | Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma | completed | Phase 2 | 70 | Leiden University Medical CenterOTHER | 2 | Apr 20, 2022 | clinicaltrials |
| NCT02050919 | Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma | completed | Phase 2 | 20 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 21, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02247544 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma(TRAVELL) | completed | Phase 2 | 105 | Italian Sarcoma GroupNETWORK | 1 | Nov 1, 2021 | clinicaltrials |
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01441635 | Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids | completed | Phase 2 | 271 | AbbVie (prior sponsor, Abbott)INDUSTRY | 0 | Jul 13, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT02301039 | SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | completed | Phase 2 | 144 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Sep 29, 2020 | clinicaltrials |
| NCT01817530 | Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF) | completed | Phase 2 | 571 | AbbVieINDUSTRY | 0 | Jul 21, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT02166411 | Laparoscopic Myomectomy Using Barbed or Conventional Sutures | completed | Phase 2 | 92 | Cairo UniversityOTHER | 1 | Mar 13, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials